GlaxoSmithKline News and Research

RSS

Genentech receives FDA approval for Kadcyla to treat HER2-positive metastatic breast cancer

The U.S. Food and Drug Administration today approved Kadcyla (ado-trastuzumab emtansine), a new therapy for patients with HER2-positive, late-stage (metastatic) breast cancer.

23 Feb 2013

GSK1322322 targets gram-positive bacteria including methicillin-resistant strains of MRSA

An increasing number of bacteria is evolving antibiotic resistance. Much-feared representatives of this steadily growing group include Staphylococci strains. At this point, multi-resistant forms of the bacterium Staphylococcus aureus - the "hospital germ" known commonly by its acronym, MRSA - can only be treated with a select subset of antibiotics as many drugs have simply stopped working. This is precisely why the field of medicine is in desperate need of new treatment options.

14 Feb 2013

Targacept reports net loss of $15.9 million for fourth quarter 2012

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today reported its financial results for the fourth quarter and year ended December 31, 2012.

14 Feb 2013

GSK, Vanderbilt partner to develop and commercialize new therapies for severe obesity

Vanderbilt University announced today that it has signed a collaboration agreement with GlaxoSmithKline (GSK) for the discovery, development and commercialization of novel therapies for severe obesity.

13 Feb 2013

GAVI Alliance to fund HPV immunization projects in 8 countries

The GAVI Alliance "is to help protect more than 180,000 girls in eight countries across Africa and Asia from cervical cancer by funding immunization projects with vaccines from Merck and GlaxoSmithKline," Reuters reports in an article examining the group's efforts to vaccinate young women with Merck's Gardasil and GSK's Cervarix, "the world's only two approved shots designed to protect against the sexually transmitted human papillomavirus (HPV) that causes the vast majority of cervical cancer cases."

5 Feb 2013

MSF claims aid for vaccines subsidizing pharmaceutical companies, Guardian reports

"Large sums of public money intended to ensure children in the developing world are immunized against disease are effectively being used to subsidize Big Pharma, doctors working in the field claim," the Guardian reports.

5 Feb 2013

Perrigo introduces generic Olux-E Foam, 0.05%

Perrigo Company today announced that it has launched clobetasol emulsion propionate foam, 0.05%, the generic equivalent of Olux -E Foam, 0.05%.

1 Feb 2013

Indian company plans to make lower-cost injectable polio vaccine

Serum Institute of India Ltd., the world's largest vaccine manufacturer, plans to "slash the price of polio immunization and introduce shots for diarrhea and pneumonia, undercutting Pfizer Inc. and GlaxoSmithKline Plc.," Bloomberg Businessweek reports.

24 Jan 2013

Studies identify cellular pathways involved in governing day-night pattern of circadian rhythms

UC Irvine-led studies have revealed the cellular mechanism by which circadian rhythms - also known as the body clock - modify energy metabolism and also have identified novel compounds that control this action. The findings point to potential treatments for disorders triggered by circadian rhythm dysfunction, ranging from insomnia and obesity to diabetes and cancer.

23 Jan 2013

Ceram to develop its Controlled Release Technology for the delivery of selected AstraZeneca compounds

AstraZeneca, a global pharmaceutical company, has signed an agreement with Ceram Research Ltd, the international materials development company, for Ceram to develop its Inorganic-based Controlled Release Technology in a feasibility study for the delivery of selected AstraZeneca compounds.

18 Jan 2013

MPL vaccine can stimulate brain's natural defense mechanisms in people with AD

A team of researchers from Universit- Laval, CHU de Qu-bec, and pharmaceutical firm GlaxoSmithKline (GSK) has discovered a way to stimulate the brain's natural defense mechanisms in people with Alzheimer's disease.

17 Jan 2013

OncoMed commences dosing in OMP-52M51 Phase 1 clinical trial for hematologic cancers

OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that patient dosing has begun in a Phase 1 clinical trial of OMP-52M51 in patients with hematologic cancers.

21 Dec 2012

GSK receives FDA approval for FLUARIX QUADRIVALENT to treat seasonal flu

GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved FLUARIX QUADRIVALENT (Influenza Virus Vaccine) for the immunisation of children (three years and older) and adults to help prevent disease caused by seasonal influenza (flu) virus subtypes A and type B contained in the vaccine.

17 Dec 2012

FDA approves GSK’s raxibacumab to treat inhalational anthrax

GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved raxibacumab for the treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.

14 Dec 2012

GSK receives FDA approval for raxibacumab to treat inhalational anthrax

The U.S. Food and Drug Administration today approved raxibacumab injection to treat inhalational anthrax, a form of the infectious disease caused by breathing in the spores of the bacterium Bacillus anthracis. Raxibacumab also is approved to prevent inhalational anthrax when alternative therapies are not available or not appropriate.

14 Dec 2012

Malaria vaccine trial: an interview with Professor Sir Brian Greenwood

Malaria is an infection caused by a parasite called plasmodium, which is transmitted from person to person by females of some species of mosquito. It is primarily a disease of tropical countries.

14 Dec 2012

Unigene announces results from oral PTH Phase 2 study on osteoporosis

Unigene Laboratories, Inc., a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that the results of its successful Phase 2 clinical trial evaluating an experimental oral parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women has been published online by Bone, the Official Journal of the International Bone and Mineral Society.

13 Dec 2012

Tiotropium benefits patients with chronic obstructive pulmonary disease

In order to widen the narrowed airways in patients with chronic obstructive pulmonary disease (COPD), tiotropium bromide (tiotropium in brief) is one of the drugs available that can be prescribed for inhalation. The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined whether tiotropium offers a perceptible advantage to patients compared to a dummy medication (placebo) and to other COPD drugs.

12 Dec 2012

Ligand commences PG-free melphalan pivotal trial in multiple myeloma

Ligand Pharmaceuticals Incorporated announced today that it has initiated a pivotal trial of Captisol-enabled, propylene glycol-free (PG-free) high-dose melphalan as a conditioning treatment prior to autologous transplant for patients with multiple myeloma.

11 Dec 2012

GSK, Fred Hutch to develop therapeutics against facioscapulohumeral muscular dystrophy

Fred Hutchinson Cancer Research Center and GlaxoSmithKline PLC (GSK) today announced a partnership to develop therapeutics to treat an inherited form of muscular dystrophy.

11 Dec 2012

GlaxoSmithKline News and Research

Genentech receives FDA approval for Kadcyla to treat HER2-positive metastatic breast cancer

GSK1322322 targets gram-positive bacteria including methicillin-resistant strains of MRSA

Targacept reports net loss of $15.9 million for fourth quarter 2012

GSK, Vanderbilt partner to develop and commercialize new therapies for severe obesity

GAVI Alliance to fund HPV immunization projects in 8 countries

MSF claims aid for vaccines subsidizing pharmaceutical companies, Guardian reports

Perrigo introduces generic Olux-E Foam, 0.05%

Indian company plans to make lower-cost injectable polio vaccine

Studies identify cellular pathways involved in governing day-night pattern of circadian rhythms

Ceram to develop its Controlled Release Technology for the delivery of selected AstraZeneca compounds

MPL vaccine can stimulate brain's natural defense mechanisms in people with AD

OncoMed commences dosing in OMP-52M51 Phase 1 clinical trial for hematologic cancers

GSK receives FDA approval for FLUARIX QUADRIVALENT to treat seasonal flu

FDA approves GSK’s raxibacumab to treat inhalational anthrax

GSK receives FDA approval for raxibacumab to treat inhalational anthrax

Malaria vaccine trial: an interview with Professor Sir Brian Greenwood

Unigene announces results from oral PTH Phase 2 study on osteoporosis

Tiotropium benefits patients with chronic obstructive pulmonary disease

Ligand commences PG-free melphalan pivotal trial in multiple myeloma

GSK, Fred Hutch to develop therapeutics against facioscapulohumeral muscular dystrophy

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News